Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Genentech, S San Francisco, United States

1 abstract

Abstract
BENEFIT OF CONTINUING TOCILIZUMAB THERAPY (8 MG/KG EVERY 4 WEEKS) IN RHEUMATOID ARTHRITIS PATIENTS WHO HAVE NOT RESPONDED ADEQUATELY WITHIN THE FIRST 8 WEEKS
Org: Mount Sinai Hosp, Toronto, Canada, Genentech, S San Francisco, United States,